- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
FDA Approves Otsuka and Lundbeck's Abilify for Schizophrenia and Bipolar I Disorder
First once-every-two-months long-acting injectable offers sustained therapeutic concentrations for patients.
Otsuka America Pharmaceutical, Inc. and Lundbeck announced the FDA's approval of Abilify (aripiprazole), the first once-every-two-months long-acting injectable (LAI) for the treatment of schizophrenia or maintenance monotherapy treatment of bipolar I disorder in adults. The extended-release injectable suspension delivers sustained therapeutic concentrations with one dose, providing continuous delivery of medication to help maintain therapeutic plasma concentrations in patients living with schizophrenia and bipolar I disorder.
The approval marks a significant milestone in offering a new treatment option for those living with these mental health conditions.
Reference: FDA Approves Otsuka and Lundbeck’s ABILIFY ASIMTUFII® (aripiprazole), the First Once-Every-Two-Months Long-acting Injectable (LAI) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults | PRINCETON, N.J. & DEERFIELD, April 27, 2023 / Business Wire
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.
